In STEP 1, patients with obesity (without diabetes) lost nearly 15% of body weight on weekly semaglutide
for some [dulaglutide (Gerstein et al., 2019), liraglutide (Marso et al., 2016) and semaglutide (Marso et al., 2017)], the CVOTs also confirmed a cardiovascular benefit and eventually led to the approved use of these GLP-1 RAs to reduce cardiovascular risk in people with type 2 diabetes and established CVD or at high cardiovascular risk (Honigberg et al., 2020)
Whichever semaglutide program you choose, check in with a licensed medical professional before starting
Retatrutide outperforms Tirzepatide in clinical weight loss trials, delivering 24.2% average weight loss compared to Tirzepatides 20.9% at maximum doses
These findings dont rule out its use, but they do mean close monitoring matters, especially if you already have heart disease or risk factors
Choosing nutrient-dense foods: Focus on vegetables, fruits, lean proteins, whole grains, legumes, nuts, and healthy fats 24 , 25